16 completed, 2 terminated, 1 recruiting. 19 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Completed 16, Terminated 2, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Caspofungin: new trials by email Literature Review of Caspofungin trials Research Report on Caspofungin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. Fosmanogepix, Caspofungin, Fluconazole - Candidemia, Candidiasis, Invasive | Phase 3 | Recruiting | Basilea Pharmaceutica | 450 | 2024-12-11 | 2026-10-19 |
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole SCY-078, Fluconazole, Echinocandin - Candidiasis, Invasive, Candidemia | Phase 3 | Terminated | Scynexis, Inc. | 68 | 2022-08-03 | 2026-08-10 |
| Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Rezafungin for Injection, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 199 | 2018-10-07 | 2023-01-06 |
| Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis - Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm | Phase 3 | Completed | Children's Oncology Group | 292 | 2013-03-21 | 2024-10-16 |
| Empirical Versus Preemptive Antifungal Therapy caspofungin acetate - Fungal Infection, Leukemia | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 556 | 2012-03-01 | 2023-12-11 |
| Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Adult Acute Monoblastic Leukemia | Phase 3 | Completed | Children's Oncology Group | 517 | 2011-04-04 | 2021-03-30 |
| Liver Transplant European Study Into the Prevention of Fungal Infection micafungin, fluconazole, liposomal amphotericin B - Liver Transplantation, Mycoses | Phase 3 | Completed | Astellas Pharma Inc | 350 | 2009-12-15 | 2024-11-18 |
| Pharmacokinetics of Caspofungin in Burn Patients Caspofungin (drug) - Thermal Injury | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 2 | 2009-02-01 | 2026-03-04 |
| A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED) caspofungin acetate, Comparator: Micafungin sodium - Fungal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 121 | 2008-08-01 | 2017-03-23 |
| A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066) caspofungin acetate - Fungal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 63 | 2008-01-01 | 2017-03-24 |
| Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections Isavuconazole, Caspofungin, Voriconazole - Candidiasis, Invasive, Candidemia | Phase 3 | Completed | Astellas Pharma Inc | 450 | 2007-03-08 | 2024-12-10 |
| Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055) MK0991, caspofungin acetate / Duration of Treatment: - Fungal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 131 | 2006-03-01 | 2015-12-17 |
| A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED) caspofungin acetate - Invasive Candidiasis | Phase 3 | Completed | Merck Sharp & Dohme LLC | 204 | 2006-01-01 | 2017-03-24 |
| A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED) caspofungin acetate - Fungal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 50 | 2005-06-01 | 2017-02-23 |
| Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units Caspofungin - Candidiasis | Phase 3 | Completed | National Cancer Institute (NCI) | 1200 | 2004-12-01 | 2008-03-04 |
| Caspofungin Study for Fungal Infections in Adults in Critical Care Settings Caspofungin, Placebo - Candidiasis | Phase 3 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 1200 | 2004-10-01 | 2014-12-05 |
| Study of Micafungin in Patients With Invasive Candidiasis or Candidemia Micafungin, Caspofungin - Candidiasis, Candidemia | Phase 3 | Completed | Astellas Pharma Inc | 611 | 2004-09-01 | 2014-09-18 |
| Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis micafungin, caspofungin - Candidiasis, Oral | Phase 3 | Completed | Astellas Pharma Inc | 454 | 2004-06-01 | 2014-08-20 |
| Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment caspofungin acetate, liposomal amphotericin B - Cancer | Phase 3 | Completed | Memorial Sloan Kettering Cancer Center | 2000-08-01 | 2013-01-18 |
Mycoses (13) · Candidemia (5) · Candidiasis, Invasive (5) · Candidiasis (4) · Invasive Fungal Infections (4) · Leukemia, Myeloid, Acute (3) · Leukemia (2) · Neutropenia (2) · Torulopsis (2) · Blast Crisis (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Candidiasis, Oral (1) · Carcinoma, Embryonal (1) · Carcinoma, Ovarian Epithelial (1)
Merck Sharp & Dohme LLC (5) · Astellas Pharma Inc (4) · Children's Oncology Group (2) · Assistance Publique - Hôpitaux de Paris (1) · Basilea Pharmaceutica (1) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Scynexis, Inc. (1)
United States (10) · France (8) · Belgium (7) · Germany (7) · Spain (6) · Canada (5) · Italy (5) · Argentina (4) · Brazil (4) · China (4) · Israel (4) · South Africa (4) · Australia (3) · Austria (3) · Bulgaria (3)
Alexandra Hill, MD (1) · Christophe Vinsonneau, MD (1) · Christopher C Dvorak (1) · David Angulo, MD (1) · Kent Sepkowitz, MD (1) · Taylor Sandison, MD, MPH (1) · Theoklis E Zaoutis (1)
PMID 15459300, PMID 21147825, PMID 22585216, PMID 23052987, PMID 23959319, PMID 25520332, PMID 25902926, PMID 30289478, PMID 31688884, PMID 33136159, PMID 33438477, PMID 35906831, PMID 36442484, PMID 38008099, PMID 38502709, PMID 38985561, PMID 39259571, PMID 39468640, PMID 39529079, PMID 41194465, PMID 41940006
U10CA095861 (2), UG1CA189955 (2), 2008 (1)